Skip to main content
Erschienen in: Discover Oncology 3/2010

01.06.2010

Risk of Mortality by Histologic Type of Breast Cancer in the United States

verfasst von: Christopher I. Li

Erschienen in: Discover Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

There are several histologic types of breast cancer that beyond their histopathologic differences have distinct clinical characteristics. However, it is unclear how histology is related to risk of mortality particularly when differences in hormone receptor status, tumor size, and nodal status are incorporated. This study utilized a cohort of 319,463 breast cancer patients ≥30 years of age diagnosed from 1992 to 2007 identified from 17 population-based cancer registries that participate in the Surveillance Epidemiology and End Results Program. Multivariate adjusted risks of mortality associated with seven breast cancer histologic subtypes were estimated using Cox regression. Mucinous, tubular, and medullary carcinomas were associated with 31–79% lower risks of mortality compared to ductal carcinoma. Inflammatory breast cancer was associated with a 50–53% increased risk of mortality depending on age. While lobular carcinomas carried the same risk of mortality as ductal carcinoma among women 30–49 years of age, among women ≥50 years of age with node-negative disease lobular carcinoma was associated with an 11% reduced risk of mortality, but among those with node-positive disease it was associated with a 10% increased risk of mortality. This study confirms that mucinous, tubular, and medullary carcinomas have a more favorable prognosis compared to ductal carcinoma, and that inflammatory carcinoma has a poorer prognosis. Though many of these histologic subtypes are quite rare, consideration of the mortality risk associated with a given subtype may be clinically useful when making decisions regarding treatment and follow-up.
Literatur
1.
Zurück zum Zitat Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16(12):2773–2780CrossRefPubMed Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16(12):2773–2780CrossRefPubMed
2.
Zurück zum Zitat Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046–1052CrossRefPubMed Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046–1052CrossRefPubMed
3.
Zurück zum Zitat Li CI, Moe RE, Daling JR (2003) Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 163(18):2149–2153CrossRefPubMed Li CI, Moe RE, Daling JR (2003) Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 163(18):2149–2153CrossRefPubMed
4.
Zurück zum Zitat Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc (B) 34:187–220 Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc (B) 34:187–220
5.
Zurück zum Zitat Rakha EA, Lee AH, Evans AJ et al (2009) Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 28(1):99–104CrossRefPubMed Rakha EA, Lee AH, Evans AJ et al (2009) Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 28(1):99–104CrossRefPubMed
6.
Zurück zum Zitat Louwman MW, Vriezen M, van Beek MW et al (2007) Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 121(1):127–135CrossRefPubMed Louwman MW, Vriezen M, van Beek MW et al (2007) Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 121(1):127–135CrossRefPubMed
7.
Zurück zum Zitat Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975CrossRefPubMed Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975CrossRefPubMed
8.
Zurück zum Zitat Dian D, Herold H, Mylonas I et al (2009) Survival analysis between patients with invasive ductal and invasive lobular breast cancer. Arch Gynecol Obstet 279(1):23–28CrossRefPubMed Dian D, Herold H, Mylonas I et al (2009) Survival analysis between patients with invasive ductal and invasive lobular breast cancer. Arch Gynecol Obstet 279(1):23–28CrossRefPubMed
9.
Zurück zum Zitat Allemani C, Sant M, Berrino F et al (2004) Prognostic value of morphology and hormone receptor status in breast cancer—a population-based study. Br J Cancer 91(7):1263–1268CrossRefPubMed Allemani C, Sant M, Berrino F et al (2004) Prognostic value of morphology and hormone receptor status in breast cancer—a population-based study. Br J Cancer 91(7):1263–1268CrossRefPubMed
10.
Zurück zum Zitat Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y (2004) Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer 90(6):1138–1143CrossRefPubMed Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y (2004) Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer 90(6):1138–1143CrossRefPubMed
11.
Zurück zum Zitat Viale G, Rotmensz N, Maisonneuve P et al (2009) Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat 117(1):211–214CrossRefPubMed Viale G, Rotmensz N, Maisonneuve P et al (2009) Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat 117(1):211–214CrossRefPubMed
12.
Zurück zum Zitat Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156CrossRefPubMed Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156CrossRefPubMed
13.
Zurück zum Zitat Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26(18):3006–3014CrossRefPubMed Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26(18):3006–3014CrossRefPubMed
14.
Zurück zum Zitat Davis RP, Nora PF, Kooy RG, Hines JR (1979) Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg 114(4):485–488PubMed Davis RP, Nora PF, Kooy RG, Hines JR (1979) Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg 114(4):485–488PubMed
15.
Zurück zum Zitat Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW (1982) Infiltrating lobular carcinoma of the breast. Histopathology 6(2):149–161CrossRefPubMed Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW (1982) Infiltrating lobular carcinoma of the breast. Histopathology 6(2):149–161CrossRefPubMed
Metadaten
Titel
Risk of Mortality by Histologic Type of Breast Cancer in the United States
verfasst von
Christopher I. Li
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Discover Oncology / Ausgabe 3/2010
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-010-0016-8

Weitere Artikel der Ausgabe 3/2010

Discover Oncology 3/2010 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.